Skip to content
Screener

Sutro Biopharma STRO Pre-Tax Income

Pre-Tax Income at other companies

Pfizer logo
PfizerPFE
-$653M-121%
Gilead Sciences logo
Gilead SciencesGILD
-$10.25B-522%
Xencor logo
XencorXNCR
-$21.92M+29.5%
Schrodinger logo
SchrodingerSDGR
$7.35M+117%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$52.84M-34.5%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$50M-144%

Other financials

Income statement

See full
Revenue$9.8M-84.6%
Operating income-$29.9M-794%
Net income-$38.5M-235%
EPS (diluted)-$2.33-72.6%

Balance sheet

See full
Cash & equivalents$54.3M-15.1%
Total debt$10.8M-45.0%
Total equity-$103.3M-222%
Total assets$194.5M-25.9%

Cash flow

See full
Operating cash flow-$38.3M+14.4%
CapEx$256.0K
Free cash flow-$38.5M+13.8%

Valuation

See full
Market cap$423.04M+546%
Enterprise value$379.49M+1,702%
P/S9.3×+8.6×

Profitability

See full
Operating margin-319.6%+540pp
Net margin-395.2%+18,070pp
FCF margin-318.2%+159pp

Returns & leverage

See full
Return on equity-234.2%
Debt / equity0.5×+0.3×
Current ratio3.3×+0.2×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Sutro Biopharma’s 10-Q, filed August 12, 2026.

Filed
Aug 12, 2026, 7:30 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-345748
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Interest income1,7232,5193,3585,708
Non-cash interest expense related to the sale of future royalties(9,862)(9,647)(19,329)(18,991)
Interest and other income (expense), net(505)(1,044)(1,516)(2,336)
Loss before provision for income taxes(38,532)(11,517)(77,031)(87,478)
Provision for / (benefit) from income taxes1(18)(14)(11)
Net loss$(38,533)$(11,499)$(77,017)$(87,467)
Net loss per share, basic and diluted$(2.33)$(1.35)$(5.19)$(10.31)
Weighted-average shares used in computing basic and diluted net loss per share16,571,6028,511,98514,836,6178,482,434

Item 1. Financial Statements.

FAQ

What is Sutro Biopharma's pre-tax income?
Sutro Biopharma (STRO) reported pre-tax income of -$38.53M in Q2 2026.
How has Sutro Biopharma's pre-tax income changed year-over-year?
Sutro Biopharma's pre-tax income decreased by 234.6% year-over-year, from -$11.52M to -$38.53M.
What is the long-term trend for Sutro Biopharma's pre-tax income?
Over 3 years (2021 to 2025), Sutro Biopharma's pre-tax income has grown at a 21.9% compound annual growth rate (CAGR), from -$105.54M to -$191.18M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Sutro Biopharma's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude